Shots:Kaigene has entered into an exclusive licensing agreement with Taisho Pharmaceutical for the exclusive development & commercialization of KG006 in JapanAs per the deal, Taisho will acquire exclusive rights to develop & commercialise KG006 in Japan, with Kaigene receiving $5M upfront, up to $22M & ¥57.5B (~$351M) in development, regulatory & sales milestones,…
